Clinical Trial Results:
            A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who are responsive to such therapy
    
|     Summary | |
|     EudraCT number | 2005-004094-25 | 
|     Trial protocol | CZ AT FI SK IE HU DE ES SE GB PT BE DK GR IT | 
|     Global completion date | 
                                    08 Apr 2013
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    13 Oct 2016
                             | 
|     First version publication date | 
                                    13 Oct 2016
                             | 
|     Other versions | |
|     Summary report(s) | Results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
